Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

Geert D’Haens(Amsterdam University Medical Centers), P. Rutgeerts

Gastroenterology

February 1, 1998

10.1016/s0016-5085(98)70476-7

Cited by 865

Related Papers

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

|The American Journal of Gastroenterology|2015|1.8k

European evidence-based Consensus on the management of ulcerative colitis: Current management

|Journal of Crohn s and Colitis|2008|558

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

|The Lancet|2022|383

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

|Gastroenterology|2016|329

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

|The Lancet|2022|312